HP
RIGL icon

HealthInvest Partners’s Rigel Pharmaceuticals RIGL Stock Holding History

HealthInvest Partners’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-109,000
Closed -$2.89M – 15
2021
Q4 		$2.89M Sell
109,000
-67,500
-38% -$2.04M 4.07% 13
2021
Q3 		$6.41M Buy
+176,500
New +$6.95M 9.6% 5

Other funds holding RIGL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

HealthInvest Partners's RIGL Position: Q1 2022 in Review

HealthInvest Partners sold out of Rigel Pharmaceuticals (RIGL) in Q1 2022, closing a stake of 109,000 shares — an estimated $2.89M sold.

HealthInvest Partners first reported a position in RIGL in Q3 2021 and held it in 2 quarters. The position peaked at $6.41M in Q3 2021. 163 funds tracked by Wall St. Rank hold RIGL as of Q1 2022.

  • HealthInvest Partners reported no remaining Rigel Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • HealthInvest Partners sold 109,000 Rigel Pharmaceuticals shares in Q1 2022, an estimated $2.89M.
  • HealthInvest Partners first reported a position in Rigel Pharmaceuticals in Q3 2021 and held it in 2 quarters.
  • HealthInvest Partners's Rigel Pharmaceuticals position peaked at $6.41M in Q3 2021.
  • 163 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q1 2022.

Based on HealthInvest Partners's 13F filing for Q1 2022, filed 5 May 2022.